Evaluation of MyoStrain™ in Clinical Practice

Sponsor
University of Kansas Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT03825224
Collaborator
(none)
19
1
7
2.7

Study Details

Study Description

Brief Summary

Evaluate MyoStrain cardiac MRI pulse sequence in Clinical practice

Condition or Disease Intervention/Treatment Phase
  • Procedure: Diagnostic Test: Myostrain

Detailed Description

Evaluate MyoStrain cardiac MRI pulse sequence in Clinical practice to determine how the use may alter treatment decisions and clinical outcomes in patients who are undergoing cardiac MRI.

Study Design

Study Type:
Observational
Actual Enrollment :
19 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Evaluation of MyoStrain™ in Clinical Practice
Actual Study Start Date :
Apr 15, 2019
Actual Primary Completion Date :
Nov 15, 2019
Actual Study Completion Date :
Nov 15, 2019

Outcome Measures

Primary Outcome Measures

  1. Evaluate workflow for MyoStrain testing [Baseline]

    Survey the CMR interpreter to see how Myostrain impacted their interpretation and survey the referring clinician after receiving the CMR report. Survey Questions using 5-point Likert and binary reporting scale. The lower numbers represent positive feedback. Example listed below: CARDIAC MRI INTERPRETATION QUESTIONS FOR READER (CARDIOLOGIST OR RADIOLOGIST) How easy was it to interpret the additional Myostrain sequence information? 1 2 3 4 5 (1=Very Helpful 2=Helpful 3=Indifferent 4=Unhelpful 5=Very Unhelpful)

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Patients already scheduled for diagnostic testing with commercially available imaging modality (cardiac MRI)

  • The patient population will include (but not limited to), those being evaluated for heart disease and heart failure that may be related to vascular disease (coronary artery disease), drug related heart failure (chemotherapy, alcohol), inflammatory systemic conditions (sarcoidosis, amyloidosis, lupus), myocarditis, and/or infectious etiologies

  • Provided written informed consent

Exclusion Criteria:
  • Contraindication to Magnetic Resonance Imaging

Contacts and Locations

Locations

Site City State Country Postal Code
1 The University of Kansas Medical Center Kansas City Kansas United States 66160

Sponsors and Collaborators

  • University of Kansas Medical Center

Investigators

  • Principal Investigator: Brian M Everist, MD, The University of Kansas Medical Center

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
University of Kansas Medical Center
ClinicalTrials.gov Identifier:
NCT03825224
Other Study ID Numbers:
  • STUDY00142902
First Posted:
Jan 31, 2019
Last Update Posted:
Nov 19, 2019
Last Verified:
Nov 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by University of Kansas Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 19, 2019